Showing posts with label sales. Show all posts
Showing posts with label sales. Show all posts

Friday, June 21, 2013

Adam Feuerstein Tweet on Belviq First Week Sales

To put this into context, Belviq was only available three days to reach 1,087 prescriptions.  It took Qsymia three weeks to get to 1,000 prescriptions.  Shares of ARNA are gapping up this morning as a result.  Shorts hoping for an unsuccessful Belviq commercial launch better cover now, because they are in for a rude awakening.

You know the tide is turning when Arena's former biggest basher has to report positive results.

Saturday, May 4, 2013

What bullion dealers are saying about gold demand

This article is a good scan for physical precious metals dealers and the current shortages in bullion coins and bars.  It's interesting that near the end of the article, the author mentions rising premiums in physical gold prices, but she doesn't mention the much larger rise in silver premiums.  I question whether the omission was accidental or intentional.

http://www.marketwatch.com/story/what-bullion-dealers-are-saying-about-gold-demand-2013-05-03

Monday, December 3, 2012

US Mint Gold and Silver Sales

Any questions?

Click on Image to Enlarge.

Tuesday, June 30, 2009

Is the biotech sector cheap?


According to Dr. Steve Sjuggerud, biotech stocks are currently cheap, based on the price/sales ratio. At the tech boom peak, the P/S ratio was over 20. Today, due to last year's massive market decline and subsequent difficult financing environment, the P/S ratio lies at 3, near it's bottom during the late 1990's.

The media and public have also become enamored with green technology and the massive government boondoggle of tax-and-spend. My personal opinion is that clean technologies like solar and wind power won't gain meaningful traction for years, if not decades, and will only exist as long as government subsidies support their money-losing business models.

Biotechs have also participated in the huge rally since March 6, up over 30%. My cohorts and I have profited immensely as a result, a product of due diligence, prescient market timing, and frankly, instincts and luck. Fear ruled the market in early March, and it just smelled overdone. The due diligence on pivotal events catalyzed the outsized gains.

To summarize, Dr. Sjuggerud likes biotech for the following reasons: they're cheap, unloved, and in an uptrend. I'm just glad my buddies and I picked up on this trend a few months ago.

Friday, February 20, 2009

Good News, Bad News...

Here in California, we got some good news.

The good news: the State Legislature passed a budget bill, resolving the $42 billion budget deficit.

The bad news: our personal income, sales, and vehicle license fee taxes will go up.

Obviously, services will be cut, but hey, at least they rejected the gasoline tax increase.